ImmunoGen

Biotech · Acquired

Mirvetuximab soravtansine, a folate receptor alpha antibody-drug conjugate (ADC) therapeutic for ovarian cancer

immunogen.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
22
0 granted · 22 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3315Hemostemix Inc.—$132K
3316Zag Bio——
3317Actinium Pharmaceuticals, Inc.—$3.3M
3318ImmunoGen——
3319Cypre, Inc.—$3.2M
3320Optimeos Life Sciences, Inc.—$3.3M
3321Applied Proteomics, Inc.—$50M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 22
  • Maytansinoid Derivatives With Self-immolative Peptide Linkers And Conjugates Thereofapplication
  • ANTI-CD123 Immunoconjugates For The Treatment Of Acute Myeloid Leukemiaapplication
  • Biparatopic Fr-alpha Antibodies And Immunoconjugatesapplication
  • Novel Processes For Preparing Camptothecin Derivativesapplication
  • Improved Methods For Preparing N-methyl Alanine Esters Of Maytansinolapplication
  • ANTI-CD123 Immunoconjugates For The Treatment Of Blastic Plasmacytoid Cell Neoplasmapplication
  • Anti-FOLR1 Immunoconjugate Dosing Regimensapplication
  • Process For Preparing Purified Drug Conjugatesapplication
  • Conjugation Methodsapplication
  • Separation Of Triple-light Chain Antibodies Using Cation Exchange Chromatographyapplication
  • Methods For Increasing Efficacy Of FOLR1 Cancer Therapyapplication
  • Improved Methods For Preparing Cytotoxic Benzodiazepine Derivativesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.